# Immune Tolerance Network UM1 2023 Supplement

> **NIH NIH UM1** · BENAROYA RESEARCH INST AT VIRGINIA MASON · 2024 · $7,500,000

## Abstract

Project Summary / Abstract
The mission of the ITN is to advance the clinical application of immune tolerance by performing
high quality clinical trials of emerging therapeutics based upon testable mechanistic hypotheses.
The ITN is structured in order to interrogate different diseases across the immunologic
spectrum, with integration of innovative clinical studies and cutting edge immunology laboratory
analysis. The ITN approach—clinical assessment of novel tolerance therapeutics, while we
simultaneously evaluate the cellular, genetic, and immunologic mechanisms of disease and how
they are altered in response to therapy—creates a framework for advancing cross-disease and
cross-discipline knowledge, all designed to accelerate therapeutic options for major diseases.
The existing scientific and operational framework enables the ITN to successfully enhance the
development of tolerance therapies in transplantation, autoimmunity, and allergy. ITN has
outlined a process to evolve our current strategies into the next generation of planned trials, as
well as to operate a nimble, future-focused organization, poised to lead and adopt innovations
that are currently unknown. The ITN has a collaborative structure involving hundreds of
investigators, advisors, and clinical sites working in tandem with a core group of ITN staff,
operating a program that is both scientifically and financially efficient. Several new innovations
recently adopted by the ITN encourage widespread involvement from academic investigators,
including expanded resource sharing and data sharing operations. With lead institutional
commitment from the Benaroya Research Institute and the University of California San
Francisco, and participation of more than 20 other major institutions represented in leadership
and major advisory roles, the ITN strives to continue to successfully pioneer high impact clinical
trials and mechanistic studies in areas of unmet medical need.

## Key facts

- **NIH application ID:** 11005185
- **Project number:** 3UM1AI109565-10S2
- **Recipient organization:** BENAROYA RESEARCH INST AT VIRGINIA MASON
- **Principal Investigator:** Mark S Anderson
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $7,500,000
- **Award type:** 3
- **Project period:** 2014-02-01 → 2028-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11005185

## Citation

> US National Institutes of Health, RePORTER application 11005185, Immune Tolerance Network UM1 2023 Supplement (3UM1AI109565-10S2). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/11005185. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*